Get the Stockscreener App
5.125
3.25%
0.165
Anteris Technologies Global Corp stock is traded at $5.125, with a volume of 34,364.
It is up +3.25% in the last 24 hours and up +26.76% over the past month.
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.
See More
Previous Close:
$4.96
Open:
$4.96
24h Volume:
34,364
Relative Volume:
0.15
Market Cap:
$184.81M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-2.5905
EPS:
-1.9784
Net Cash Flow:
-
1W Performance:
+20.79%
1M Performance:
+26.76%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$4.8654
$5.15
1-Week Range:
$4.0518
$5.15
52-Week Range:
$2.34
$8.79
Anteris Technologies Global Corp Stock (AVR) Company Profile
Name
Anteris Technologies Global Corp
Sector
Industry
Phone
651-493-0606
Address
860 BLUE GENTIAN ROAD, EAGAN
Compare AVR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVR
Anteris Technologies Global Corp
|
5.125 | 162.09M | 0 | 0 | 0 | -1.9784 |
|
ISRG
Intuitive Surgical Inc
|
560.64 | 199.19B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
172.74 | 49.82B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.50 | 42.71B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
251.99 | 35.94B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
222.52 | 15.12B | 2.90B | 467.20M | 306.90M | 6.37 |
Anteris Technologies Global Corp Stock (AVR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | Lake Street | Buy |
| Jan-07-25 | Initiated | Barclays | Overweight |
| Jan-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-07-25 | Initiated | TD Cowen | Buy |
Anteris Technologies Global Corp Stock (AVR) Latest News
Anteris Technologies Expands CDI Issuance in Strategic Securities Adjustment - TipRanks
Anteris Technologies Announces Cessation of Securities - TipRanks
Analyzing MSA Safety (NYSE:MSA) & Anteris Technologies Global (NASDAQ:AVR) - Defense World
Anteris Technologies Global Corp’s Lock-Up Period Set To End on June 11th (NASDAQ:AVR) - Defense World
Millennium Management LLC Purchases Shares of 313,298 Anteris Technologies Global Corp (NASDAQ:AVR) - Defense World
Will Anteris' DurAVR Spark A Paradigm Shift In The Transcatheter Aortic Valve Replacement Landscape? - RTTNews
Citadel Advisors LLC Makes New Investment in Anteris Technologies Global Corp (NASDAQ:AVR) - Defense World
Critical Survey: Anteris Technologies Global (NASDAQ:AVR) and Vicarious Surgical (NYSE:RBOT) - Defense World
Anteris Technologies advances toward PARADIGM trial after key regulatory and clinical milestones - Proactive financial news
Anteris Technologies Issues New Employee Incentive Securities - TipRanks
The morning catch up: ASX to extend gains as global optimism lifts markets - Proactive financial news
Anteris scales for pivotal PARADIGM Trial, plunging R&D investment into clinical activities - Proactive financial news
Anteris Technologies Advances Clinical Trial Efforts with DurAVR® THV - TipRanks
Anteris Technologies Reports Q1 2025 Results and Strategic Fund Allocation - TipRanks
Anteris Announces Results for the First Quarter of 2025 - The Manila Times
Earnings calendar for: - Yahoo
Anteris Technologies Files Amendment to Annual Report - TipRanks
Anteris Technologies Announces Cessation of Certain Securities - TipRanks
Anteris Technologies Global Corp. (AVR) Receives a Buy from Lake Street - The Globe and Mail
ASX Runners of the Week: Redstone Resources, Anteris & Jindalee Lithium - businessnews.com.au
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target - Investing.com
Anteris Technologies Announces New Securities Quotation - TipRanks
NanoVibronix (NASDAQ:NAOV) & Anteris Technologies Global (NASDAQ:AVR) Head to Head Review - Defense World
Anteris Technologies Reports March 2025 CDI Adjustments - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV By Investing.com - Investing.com Canada
Anteris reports over 100 patients treated with new heart valve By Investing.com - Investing.com South Africa
Anteris Technologies Hits Milestone with DurAVR® Heart Valve Treatment - Zenopa
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV - GlobeNewswire
Anteris reports over 100 patients treated with new heart valve - Investing.com
Anteris Technologies announces 100 patients treated with DurAVR THV - TipRanks
Anteris Technologies Achieves Key Milestone in Cardiac Care - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV - Investing.com
Anteris Technologies marks clinical milestone with more than 100 patients treated using flagship DurAVR® THV - Proactive financial news
Anteris Technologies Achieves Milestone with DurAVR® Heart Valve - TipRanks
ASX Health Stocks: Anteris plans for US IPO and listing on Nasdaq - MSN
Head to Head Survey: Anteris Technologies Global (NASDAQ:AVR) & United Health Products (OTCMKTS:UEEC) - Defense World
Anteris Technologies reports one-year patient outcomes for DurAVR THV - TipRanks
Anteris shares rise on positive valve trial results By Investing.com - Investing.com Canada
Anteris Reports One-Year Patient Outcomes for DurAVR® THV - The Manila Times
Anteris shares rise on positive valve trial results - Investing.com India
Anteris Technologies Unveils Positive DurAVR® Patient Outcomes - TipRanks
Anteris Technologies Global Corp Stock (AVR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anteris Technologies Global Corp Stock (AVR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Paterson Wayne | Chief Executive Officer |
Mar 05 '25 |
Option Exercise |
7.13 |
233,000 |
1,661,290 |
233,000 |
| Denaro Stephen | Director |
Mar 11 '25 |
Option Exercise |
7.13 |
16,500 |
117,645 |
23,722 |
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):